The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury.
Keith Elliston, president and CEO of Genstruct, said: “This extended relationship with Pfizer provides for the continued application of our systems biology technology to Pfizer’s R&D programs to better predict potential drug toxicities prior to testing of new medicines in humans.”